Recursion Appoints Two Industry Leaders to Board of Directors, Enhancing Tech-Enabled Drug Discovery Capabilities

Leading digital biology company, Recursion, has announced the appointment of R. Martin Chavez and Terry-Ann Burrell to its board of directors, further solidifying its position in tech-enabled drug discovery. Both new board members bring extensive experience in innovative technology and finance, with Chavez known for pushing the boundaries of technology at Goldman Sachs and Burrell being a well-regarded financial industry veteran with expertise in biotechnology and pharmaceuticals.

Key Takeaways:

• R. Martin Chavez, former chief financial officer, chief information officer, and global co-head of the Securities Division at Goldman Sachs, joins Recursion's board of directors, bringing his expertise in using data, software, and machine learning to solve hard problems.
• Terry-Ann Burrell, former managing director of J.P. Morgan and now CFO of Beam Therapeutics, joins Recursion's board, bringing her expertise in the biotechnology and pharmaceutical industries, with experience advising clients on transaction considerations and engaging with over 100 companies.
• Recursion's platform technology and target-agnostic approach to drug discovery is more critical than ever, as highlighted by Burrell, who feels privileged to support the team's efforts in rapidly identifying targets and advancing new therapeutics.
• Chavez is a trailblazer in bringing technology to Wall Street, revolutionizing how capital moves throughout the globe, and has held various senior roles at Goldman Sachs, including CIO, CFO, and global co-head of the Securities Division.
• Chavez serves on the Board of Overseers of Harvard University, the Stanford Medicine Board of Fellows, and the Board of Trustees of the Institute for Advanced Study, highlighting his commitment to innovation and education.
• Recursion's board now includes Dr. Rob Hershberg, previously an executive at Celgene, adding to the wealth of operating experience and diverse backgrounds gained by the company.
• Recursion's mission remains to decode biology, advance new therapeutics, and lower the cost of drugs, with its ambition to bring more medicines to patients driving its growth and innovation.

Statistics:

• Recursion has a 4 petabyte database of biological images generated in-house on its robotics platform, enabling advanced machine learning approaches.
• Recursion's platform technology has the potential to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, ultimately advancing new therapeutics.

Sources:

• Recursion Press Release (May 5)
• Contify.com (Copyright 2017)
• Recursion (www.recursionpharma.com)
• Twitter ( @RecursionPharma )
• LinkedIn ( Recursion )